The Innovadores supplement of the newspaper La Razón has done a feature on Syna Therapeutics, joint venture of Reig Jofre and Leanbio created in 2018, explaining that the company is developing two biosimilar drugs for haemostasis and immuno-oncology.

Going from research to industrialisation and marketing with biosimilars was complicated in Spain before Syna was founded. Nowadays, Reig Jofre and Leanbio bring their expertise to the table to address the whole value chain and bring these drugs to patients.

Developing top-quality biosimilars and innovative molecules is a growing line of business in the pharmaceutical market to treat serious diseases. “Biosimilar drugs can cut healthcare costs by up to 35% and, therefore, help make national healthcare systems more sustainable and efficient,” notes Syna CEO Andreu Soldevila.

In order to tackle the clinical phases of these new therapies, Syna is looking for a new partner to bring in €6 million in capital.

Read the full article (in Spanish)

Photo: Andreu Soldevila, CEO of Syna, at the Barcelona Science Park - © Syna Therapeutics